Unigene Successfully Completes Phase I/II Clinical Study For Oral Calcitonin (Lufee.com)

Lufee categories

Unigene Successfully Completes Phase I/II Clinical Study For Oral Calcitonin
Unigene Laboratories, Inc. (OTCBB: UGNE) has successfully completed the Phase I/II oral calcitonin clinical study that it initiated last month. This study, which achieved all of its planned objectives, primarily measured the ability of Unigene's proprietary oral delivery technology to significantly reduce the levels of an established biochemical marker that correlates with bone loss. All of the twenty-two subjects who completed the study demonstrated a robust reduction in this marker.
- Discuss this news

Tell-a-friend about Lufee and this article

You are not logged in to Lufee at this moment. But you can tell a friend about this headline and send him an e-mail with your personal comment.

You still don't have a Lufee Account?

Sign up now and...

Get your personal account for free and sign up today. The sign up process will take you less than 5 minutes.

Signup here for free

Read what other users has to say

Nobody has posted a comment yet. Be the first to leave feedback on this news.

Read other headlines

New users at Lufee